.jpg)
Invest in the Future of Oncology
Investment Opportunity
De-risked asset, on market as early as 2029
At Glycyx, we've strategically mitigated investment risks through advanced clinical progress, a robust intellectual property portfolio, strategic partnerships, and lean development.
Significant market potential in broad use for Opioid Induced Immunotherapy Failure
The U.S. cancer treatment market, dominated by immune checkpoint inhibitors (ICIs), reached $32B in sales in 2023. Axelopran's unique position in this market for broad use across multiple cancers creates a significant market opportunity.
Competitive Landscape and Differentiation
Amid a dynamic competitive landscape, Glycyx stands out by directly addressing the opioid-induced suppression of immune responses—a critical, unmet need in cancer care. Our comprehensive patent portfolio ensures exclusive market rights for opioid antagonists used with cancer therapies, paving the way for significant market penetration.
